AMR and Cancer - Defining the Problem

Antimicrobial resistance (AMR) is an increasingly important challenge in cancer care, influencing infection risk, treatment delivery, patient outcomes, and supportive care strategies across the oncology pathway. This three-part webinar series is designed for scientists and researchers with an interest in AMR who want to better understand the clinical realities, emerging evidence, and future challenges at the intersection of infection and cancer.

Bringing together experts in oncology, infectious diseases, immunology, and antimicrobial stewardship, the series will explore why cancer patients are uniquely vulnerable to resistant infections, how antimicrobials influence treatment outcomes, and what future models of stewardship could look like in oncology and palliative care settings.

The series is chaired by Prof Anna Olsson Brown and kindly supported by an educational grant from bioMérieux. 

As part of the Microbiology Society's Knocking out AMR project, the Society presents 'Defining the Problem'. 
For this webinar, we have speakers:

Prof Anna Olsson-Brown, Professor of Clinical Cancer Trials and a Consultant in Medical Oncology, 

Dr Helena Carreira, Assistant Professor of Epidemiology, London School of Hygiene and Tropical Medicine.

This opening session will examine the growing relevance of AMR in cancer care. Speakers will discuss the scale of the problem, the evidence linking resistant infections to outcomes in oncology patients, and the complex relationship between antimicrobial use and cancer treatment success. The webinar will also explore the clinical balance between minimising AMR risk while maintaining life-saving treatment pathways and improving patient prognoses.